Nureca raised its Punjab plant budget 28%. It calls the first number a typo.
The corrected outlay is ₹128 cr. The initial ₹100 cr disclosure was a mistake, the company says.
— 3 earlier stories on Nureca Ltd. →What's new
- Nureca raised its Punjab plant capex from ₹100 cr to ₹128 cr, calling the first number a typo.
- The ₹28 cr uplift is 12% of the company’s ₹233 cr market cap.
- The board also approved buying adjoining land for future expansion at the same site.
Why this matters
A correction to a disclosure made days ago is a strange way to communicate a 28% budget increase. For a company worth ₹233 cr, deploying ₹128 cr into a single plant is a bet-the-company move. The balance-sheet load just got heavier.
What we're watching
- How Nureca funds the ₹128 cr outlay — debt, internal accruals, or another equity raise.
- The timeline for commissioning the Sundran plant and first revenue from it.
- Whether any further cost revisions emerge as construction proceeds.
The full read
Nureca quietly bumped its Punjab capex from ₹100 cr to ₹128 cr, calling the initial figure a typo. The ₹28 cr increase is 12% of its ₹233 cr market cap. The total commitment now exceeds 50% of the company’s entire value. For a nano-cap, that is a heavy bet on one manufacturing site. The Sundran plant will make medical devices and hygiene products, and the board also signed off on buying adjoining land for future expansion. The open question is funding. A ₹128 cr outlay will strain the balance sheet unless Nureca raises fresh capital. A cost overrun explained by a typo is a red flag for execution. Hardly routine.
Questions answered
- Why did Nureca revise the capex figure upwards so soon after the original disclosure?
- The company says the ₹100 cr figure in the May 29 board disclosure was a typographical error. The corrected, approved amount is ₹128 cr, a 28% increase.
- How large is this investment relative to Nureca’s size?
- The ₹128 cr capex is over 50% of Nureca’s ₹233 cr market capitalization. The ₹28 cr increase alone is 12% of its market value.
- What will the money be spent on?
- Plant and machinery to produce medical devices, healthcare consumables, and hygiene products at the Sundran, Dera Bassi site. The board also approved buying adjacent land for future expansion.
- Is this a new project or an expansion of an existing plan?
- It is a revision of the plan disclosed on May 29, with the budget raised by 28%. The strategic direction is the same; the scale is larger.
Story so far
All notes on NURECA →- 1 Jun 2026 · 6:38 PM IST Nureca raised its Punjab plant budget 28%. It calls the first number a typo.
- today Nureca promoter buys 60,842 shares, nudging stake to 34.35%
- 11d ago Nureca posts FY25 results and adds a whole-time director
- 11d ago Nureca's ₹100 cr capex is 37% of its market cap. The CFO is leaving.